BRPI0809996B8 - compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticas - Google Patents
compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticasInfo
- Publication number
- BRPI0809996B8 BRPI0809996B8 BRPI0809996A BRPI0809996A BRPI0809996B8 BR PI0809996 B8 BRPI0809996 B8 BR PI0809996B8 BR PI0809996 A BRPI0809996 A BR PI0809996A BR PI0809996 A BRPI0809996 A BR PI0809996A BR PI0809996 B8 BRPI0809996 B8 BR PI0809996B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- alopecia
- diabetes
- stroke
- viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
compostos. a presente invenção refere-se a compostos de fórmula (i) em que: r1 e r2 são cada qual independentemente h, alquila ou haloalquila r3 e r4 são cada qual independentemente h, haloalquila ou arila; r5 é alquila ou cicloalquilaquila ou cicloalqui-alquila cada das quais pode ser opcionalmente substituída com um ou mais grupos oh, r6 é selecionado a partir de ciclopropilamino, ciclopropilmetilsmino, ciclobutilamino, ciclobutilmetialamino e fórmula (a) em que um dentre x,y,e z é n e os restantes saõ cr9, r7, r8 e cada são independentemente h alquila ou haloalquila, em que pelo menos um dentre r7, r8, e cada r9 é diferente de h.um outro aspectro da invenção refere-se ás composições farmacêuticas que compreendem compostos de fórmula (i) e o uso dos referidos compostos no tratamento de distúrbios proliferativos distúrbios virais, acidente vascular cerebral, alopecia, disturbios dos cns, distúrbios neurodegenerativos, ou diabetes.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92189707P | 2007-04-04 | 2007-04-04 | |
| GB0706632.7 | 2007-04-04 | ||
| US60/921,897 | 2007-04-04 | ||
| GBGB0706632.7A GB0706632D0 (en) | 2007-04-04 | 2007-04-04 | New purine derivatives |
| PCT/GB2008/001173 WO2008122767A2 (en) | 2007-04-04 | 2008-04-02 | 2, 6, 9-substituted purine derivatives having anti proliferative properties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0809996A2 BRPI0809996A2 (pt) | 2014-10-14 |
| BRPI0809996B1 BRPI0809996B1 (pt) | 2019-09-03 |
| BRPI0809996B8 true BRPI0809996B8 (pt) | 2021-05-25 |
Family
ID=38090893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0809996A BRPI0809996B8 (pt) | 2007-04-04 | 2008-04-02 | compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8592581B2 (pt) |
| EP (1) | EP2139893B1 (pt) |
| JP (1) | JP5466145B2 (pt) |
| CN (1) | CN101679434B (pt) |
| AU (1) | AU2008235361B2 (pt) |
| BR (1) | BRPI0809996B8 (pt) |
| CA (1) | CA2681529C (pt) |
| ES (1) | ES2427845T3 (pt) |
| GB (1) | GB0706632D0 (pt) |
| MX (1) | MX2009010660A (pt) |
| PL (1) | PL2139893T3 (pt) |
| RU (1) | RU2461559C2 (pt) |
| WO (1) | WO2008122767A2 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219054D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
| GB0903346D0 (en) | 2009-02-27 | 2009-04-08 | Cambridge Advanced Tech | Transgenic Plants |
| GB201001075D0 (en) * | 2010-01-22 | 2010-03-10 | Cyclacel Ltd | Crystalline forms |
| DE102011111400A1 (de) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
| US9579198B2 (en) | 2012-03-01 | 2017-02-28 | Twelve, Inc. | Hydraulic delivery systems for prosthetic heart valve devices and associated methods |
| PL3244891T3 (pl) | 2015-01-16 | 2022-12-27 | The General Hospital Corporation | Związki poprawiające splicing mRNA |
| WO2017146253A1 (ja) | 2016-02-26 | 2017-08-31 | 公益財団法人がん研究会 | Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系 |
| KR102524773B1 (ko) * | 2017-01-26 | 2023-04-21 | 싸이클라셀 리미티드 | 퓨린 유도체의 제조 방법 |
| EP3388432A1 (en) | 2017-04-10 | 2018-10-17 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders |
| AU2019374142A1 (en) | 2018-11-01 | 2021-05-27 | Syros Pharmaceuticals, Inc. | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (CDK7) |
| RU2754441C2 (ru) * | 2019-12-30 | 2021-09-02 | Закрытое Акционерное Общество "Биокад" | Новые ингибиторы cdk8/19 |
| GB202000901D0 (en) | 2020-01-22 | 2020-03-04 | Cyclacel Ltd | Process |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| WO2024105159A1 (en) * | 2022-11-16 | 2024-05-23 | University Of Zurich | Ligands of the m6a-rna readers |
| AU2023393410A1 (en) | 2022-12-16 | 2025-07-31 | Astrazeneca Ab | 2,6,9-trisubstituted purines |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2741881B1 (fr) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| US6790958B2 (en) * | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
| US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| WO2000044750A1 (en) * | 1999-02-01 | 2000-08-03 | Cv Therapeutics, Inc. | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a) |
| US6627633B2 (en) * | 1999-03-17 | 2003-09-30 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
| WO2003002565A1 (en) * | 2001-06-27 | 2003-01-09 | Cyclacel Limited | 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders |
| US6812232B2 (en) * | 2001-09-11 | 2004-11-02 | Amr Technology, Inc. | Heterocycle substituted purine derivatives as potent antiproliferative agents |
| US6667311B2 (en) * | 2001-09-11 | 2003-12-23 | Albany Molecular Research, Inc. | Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents |
| US20030229105A1 (en) * | 2002-05-21 | 2003-12-11 | Cyclacel Limited | Treatment of autoimmune disorders |
| GB0219052D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
| GB0219054D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
| JP2006516561A (ja) * | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類 |
| ES2403558T3 (es) * | 2004-08-27 | 2013-05-20 | Cyclacel Limited | Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias |
| GB0706633D0 (en) * | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
-
2007
- 2007-04-04 GB GBGB0706632.7A patent/GB0706632D0/en not_active Ceased
-
2008
- 2008-04-02 BR BRPI0809996A patent/BRPI0809996B8/pt not_active IP Right Cessation
- 2008-04-02 ES ES08718980T patent/ES2427845T3/es active Active
- 2008-04-02 RU RU2009140753/04A patent/RU2461559C2/ru active
- 2008-04-02 MX MX2009010660A patent/MX2009010660A/es active IP Right Grant
- 2008-04-02 CA CA2681529A patent/CA2681529C/en active Active
- 2008-04-02 AU AU2008235361A patent/AU2008235361B2/en not_active Ceased
- 2008-04-02 WO PCT/GB2008/001173 patent/WO2008122767A2/en not_active Ceased
- 2008-04-02 PL PL08718980T patent/PL2139893T3/pl unknown
- 2008-04-02 CN CN2008800189406A patent/CN101679434B/zh not_active Expired - Fee Related
- 2008-04-02 EP EP08718980.9A patent/EP2139893B1/en active Active
- 2008-04-02 JP JP2010501585A patent/JP5466145B2/ja not_active Expired - Fee Related
-
2009
- 2009-10-05 US US12/573,337 patent/US8592581B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2461559C2 (ru) | 2012-09-20 |
| EP2139893A2 (en) | 2010-01-06 |
| GB0706632D0 (en) | 2007-05-16 |
| US20100093769A1 (en) | 2010-04-15 |
| CA2681529C (en) | 2015-06-30 |
| HK1139939A1 (en) | 2010-09-30 |
| EP2139893B1 (en) | 2013-06-19 |
| ES2427845T3 (es) | 2013-11-04 |
| JP5466145B2 (ja) | 2014-04-09 |
| AU2008235361A1 (en) | 2008-10-16 |
| WO2008122767A2 (en) | 2008-10-16 |
| MX2009010660A (es) | 2010-02-17 |
| CN101679434A (zh) | 2010-03-24 |
| AU2008235361B2 (en) | 2013-02-14 |
| CA2681529A1 (en) | 2008-10-16 |
| PL2139893T3 (pl) | 2013-11-29 |
| RU2009140753A (ru) | 2011-05-10 |
| US8592581B2 (en) | 2013-11-26 |
| BRPI0809996B1 (pt) | 2019-09-03 |
| WO2008122767A3 (en) | 2008-12-31 |
| BRPI0809996A2 (pt) | 2014-10-14 |
| CN101679434B (zh) | 2013-09-25 |
| JP2010523534A (ja) | 2010-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0809996B8 (pt) | compostos, seus usos para tratar um distúrbio proliferativo, viral, neurodegenerativo, do snc, diabetes, alopecia e um acidente vascular cerebral, e composições farmacêuticas | |
| BR112014023384A8 (pt) | inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos. | |
| BR112022021962A2 (pt) | Imidazopiridazinas como moduladores de il-17 | |
| BRPI0811280B8 (pt) | compostos amino-heterocíclicos, composição farmacêutica que os compreende e usos dos referidos compostos | |
| BR112014004504A2 (pt) | "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase" | |
| BR112014007193A2 (pt) | derivados de pirazoloquinolinona, preparação dos mesmos e uso terapêutico dos mesmos | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112015025766A2 (pt) | derivado de nucleosídeo altamente ativo para o tratamento de hcv | |
| BR112014011850A2 (pt) | derivados de aminopirimidina como moduladores de lrrk2 | |
| CL2008002271A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida o su sal farmaceutica; proceso de preparacion; compuestos intermediarios; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar un trastorno del sistema nervioso central tal como alzheimer, demencia senil, parkinson. | |
| BR112013020620A2 (pt) | análogos de ácido 4-hidroxibutírico | |
| BR112015014333A2 (pt) | compostos antivirais | |
| BR112015020772A2 (pt) | compostos de pirimidina e piridina e seu uso | |
| BRPI0709773B8 (pt) | derivados de malonamida, processo de produção do mesmo, medicamento, e seus usos como inibidores de gama-secretase no tratamento do mal de alzheimer | |
| BRPI0407976A (pt) | tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6 | |
| BR112014004319A2 (pt) | compostos e composições como inibidores de c-kit cinase | |
| BR112014000792A2 (pt) | compostos de piperidinila para uso como inibidores da tanquirase | |
| BR112015008717A2 (pt) | composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii | |
| BR112012028445A2 (pt) | compostos de heteroarila bicíclica como moduladores de gpr119 | |
| BRPI0513379A (pt) | derivados de sulfonamida | |
| BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
| BR112014031969A2 (pt) | derivados de pirimidinona como agentes antimaláricos | |
| ECSP088257A (es) | Derivados de amida | |
| BR112015022849A2 (pt) | sais de adição de base de nitroxolina e usos dos mesmos | |
| ATE543799T1 (de) | Piperidinyl- und piperazinylmodulatoren von g- sekretase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: CANCER RESEARCH TECHNOLOGY LTD (GB) , CYCLACEL LIM |
|
| B25G | Requested change of headquarter approved |
Owner name: CANCER RESEARCH TECHNOLOGY LTD (GB) , CYCLACEL LIM |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |